Abstract:e17513 Background: Camrelizumab (a programmed death 1 [PD-1] inhibitor) plus apatinib (a vascular endothelial growth factor receptor 2 [VEGFR2] inhibitor) showed promising efficacy and safety profiles in patient with advanced cervical cancer in the CLAP study (NCT03816553). Herein we present updated efficacy and safety data with more than 24 months of additional follow-up, and outcomes for patients retreated with ICIs following disease progression. Methods: In this single-arm phase 2 trial, 45 patients received camrelizumab (200 mg intravenously, q2w) and apatinib (250 mg orally, qd) on a 4-week cycle until disease progression, unacceptable toxicity, withdrawal of consent, or up to 2 years. For patients who completed 2 years treatment and were considered to benefit from continuing treatment, a one-year extension treatment would be provided if the patients agreed. Results: At the data cutoff (August 31, 2022), the median duration of follow-up was 11.9 (range, 1.0–43.9) months. Nine (20.0%) patients completed 2-year treatment (eight entered the one-year extension treatment, of which five completed and three discontinued due to disease progression) and 36 (80.0%) discontinued treatment (24 [53.3%] disease progression, 4 [8.9%] adverse events, 5 [11.1%] patient refusal, and 3 [6.7%] withdrawal of consent). The median duration of treatment was 6 (range, 0.9–37.4) months. The confirmed objective response rate was 55.6% (95% CI: 40.0, 70.4) that was unchanged from previous report, including two (4.4%) complete response (CR) and 23 (51.1%) partial response (PR). The median duration of response was 16.6 (95% CI, 5.6–29.9) months among 25 responders. Median progression-free survival (PFS) was 8.9 (95% CI, 5.6–18.1) months; the 12-month PFS rate was 40.7% (95% CI, 25.2–55.6). The median overall survival (OS) was 15.9 (95% CI, 9.3–36.9) months; the 24-month OS rate was 46.4% (95% CI, 30.1–61.1). Age > 50, programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 1, CPS ≥ 10, TMB-high, and PIK3CA mutation were associated with longer OS. Seven patients were retreated with the same or other ICIs after disease progression. All of them showed initial response (one CR and 6 PR) to study treatment, then had progressive disease (PD) and discontinued treatment. Of the seven patients, six achieved stable disease and one had PD following ICIs retreatment. Four patients died and three were alive at the data cutoff. Two patients received ICIs retreatment for more than 20 months, one of which was still on ICIs retreatment. No new safety signals were identified with additional 24-month follow-up. Conclusions: This long-term follow-up data demonstrate sustained and durable efficacy of camrelizumab plus apatinib, with no new safety signals, in patients with advanced cervical cancer who progressed after prior platinum-based chemotherapy. Clinical trial information: NCT03816553 .

Response and re-treatment response to immune checkpoint inhibitor treatment in advanced cervical cancer: A follow up study.

Immune checkpoint inhibitor therapy in advanced cervical cancer: Deepened response with prolonged treatment and repeat response to re-initiation of therapy

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study

The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer

Long-term survival outcomes and immune checkpoint inhibitor (ICI) retreatment in patients with advanced cervical cancer who received camrelizumab plus apatinib in the CLAP study.

Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC

Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials

Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study

Treatment Patterns and Outcomes of Immunotherapy in Extensive‐stage Small‐cell Lung Cancer Based on Real‐world Practice

Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer

Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study

Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis

Survival Outcome of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Achieved Remission During Immune Checkpoint Inhibitors Treatment.

948P Pre-treatment Characteristics and Long-Term Outcomes of Recurrent-Metastatic Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors

Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study

Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis

Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma

Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study

Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study

Immune Checkpoint Inhibitor (Ici)-Based Treatment Beyond Progression with Prior Immunotherapy in Patients with Stage IV Non-Small Cell Lung Cancer: a Retrospective Study.